CME CirclePrint this Activity for Offline ReferenceInstructions on Taking Medscape CME

Optimizing Treatment Strategies in Breast Cancer: Use of Minimally Invasive Techniques/Gene Expression Profiling to Predict Response and Prognosis CME
Chairperson: Anthony Lucci, Jr, MD; Faculty: Richard J. Cote, MD, FRCPath; Jenny C. Chang, MD; Matthew J.C. Ellis, MD, PhD
Disclosures

Release Date: March 31, 2003Valid for credit through March 31, 2004

This activity has expired.
CME in this activity indicates that it was developed according to ACCME guidelines and was certified for credit by one or more accredited CME or CE providers. Medscape cannot attest to the timeliness of expired CME activities.


This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Optimizing Treatment Strategies in Breast Cancer: Use of Minimally Invasive Techniques/Gene Expression Profiling to Predict Response and Prognosis" during the 25th Annual San Antonio Breast Cancer Symposium official CME satellite symposium at the Marriott Rivercenter Hotel in San Antonio, Texas on December 14, 2002.

Contents of This CME Activity
This program is offered in two formats. Please choose one of the versions:

    Flash Version
    (A multimedia presentation with synchronized audio, slides and transcript.)
    Note: Macromedia's Flash Player 5 plug-in is required to view the Flash version.
    Download the Macromedia Flash Player 5 plug-In:

    Get Flash 5

    --OR--

    Slides with transcript and RealAudio:

  1. Introduction
    by Anthony Lucci, Jr, MD
    Optimizing Treatment Strategies for Breast Cancer
    The Role of Expanded Treatment Options

  2. Occult Micrometastases in the Sentinel Node: Identifying Prognostic Significance
    by Anthony Lucci, Jr, MD
    Prognostic Significance of Micrometastases in the Sentinel Node
    Techniques for Detecting Metastases in Breast Cancer
    Multisectioning and Increased Yield
    Detecting Micrometastases by Immunohistochemical Analysis
    Relationship of Micrometastases Detection to Survival
    Study Findings: Significance of Sentinel Node Micrometastases
    Sentinel Node vs Axillary Dissection
    History and Controversy in Sentinel Node Dissection
    Lymph Node Analysis and Recommendations

  3. Occult Metastases in Bone Marrow Cells: Role in Early Detection and Prognosis
    by Richard J. Cote, MD, FRCPath
    Issues in the Detection of Occult Metastases in Early Stage Breast Cancer
    Detecting the Presence of Occult Metastases in Bone Marrow Cells
    Detecting the Presence of Occult Metastases in Lymph Nodes
    Detection Methods and Markers for Metastatic Disease
    Current Research: American College of Surgeons Oncology Group
    Future Research: New Directions and Markers

  4. Predicting Response and Resistance to Endocrine and Cytotoxic Therapy
    by Jenny C. Chang, MD
    Looking at Risk Models
    Analysis of Node-Negative Response to Therapy
    Resistance and Relapse to Endocrine Therapy
    A New Therapeutic Option
    How Do We Predict Who Will Relapse or Develop Resistance?
    Identifying Genetic Patterns Predictive of Sensitivity and Resistance to Docetaxel
    Analysis and Results of Gene Expression Array
    Cross-Validation Studies and Analyses
    Future Directions and Prediction Methods of Response

  5. Gene Array Expression: Detecting Response and Resistance to Aromatase Inhibition
    by Matthew J. C. Ellis, MD, PhD
    Applying Gene Array Expression in Cancer Therapy and Profiling
    Comparison of Letrozole and Tamoxifen in Inoperable Estrogen-Receptor-Positive Tumors
    Methods of Tumor Profiling
    Cell Cycle Response to Therapy
    Potential Uses of Dynamic Tumor Profiling
    Study of Neoadjuvant Endocrine Therapy With Letrozole
    Looking at Tumors From the Inside Out
    What Does the Future Hold for Genetic Profiling?

These educational activities, certified by accredited providers, were not prepared by Medscape's editors, but are made available on our site as a service to our audience. Authors are routinely instructed by the provider to disclose significant financial relationships and mention of investigational drugs and unapproved indications. Medscape has received a fee for posting these activities. Direct questions or comments to: CME@webmd.net.

 
Legal Disclaimer
The contributing faculty developed the content independently. All materials are included with permission. The material presented here does not necessarily reflect the views of Medscape, The Chatham Institute, the companies providing educational grants or the authors and writers. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information and consult a qualified healthcare professional before treating patients or utilizing any therapeutic product discussed in this educational activity.

 
Copyright © 2003 by The Chatham Institute.



Astra Zeneca Pharmaceutical LP

  • This activity has expired.

    The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.

  • CME Information
All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.